| |
Unleash the Full Potential of Your Data! Our BioELN Solution maximizes your success with efficient resources and knowledge management. Transform data into discoveries with Signals Notebook. Learn more in our white paper.
|
|
Today's Big NewsMay 10, 2023 |
|
Wednesday, May 17, 2023 2:00pm ET / 11:00am PT Join this webinar to learn more about the opprtunity medical affairs teams and medical science liaisons (MSLs) have to engage with HCPs in clinical discussions and bridge care gaps by providing crucial insights into evidence-based medicine. Register now to learn more.
|
|
| By Annalee Armstrong An FDA committee will consider whether evidence supports the benefits and risks of Sarepta's DMD gene therapy on Friday. The agency seems unconvinced. |
|
|
|
By Andrea Park Better late than never. A year after Fitbit secured the FDA’s signoff for an algorithm built into its eponymous smartwatches that can spot potential signs of atrial fibrillation—and about half a decade after the Apple Watch did the same—Samsung has achieved the milestone, too. |
By Zoey Becker With a new CEO at the helm and its growth drivers firing in the first quarter, Teva plans to debut its new strategic framework next week. |
By Gabrielle Masson All the rumors are true. After months of sale speculation, Syneos Health has officially been snapped up by three private investment firm affiliates for the eye-watering sum of $7.1 billion. |
|
Tuesday, May 23, 2023 | 2pm ET / 11am PT Clinical trials are complex, time-consuming, and costly. But what if you could use simulation to guide your decisions and optimize your trial design? In this webinar, we'll discuss the power of simulation-guided trial design (SGTD) and explain its benefits to clinical development strategies. Register now to join us.
|
|
By Andrea Park Only a few years after Siemens Healthineers put down $1.1 billion to pick up Corindus and its robotic-assisted endovascular surgery system, the medtech giant is tightening the technology’s scope. |
By Kevin Dunleavy Swedish blood disorder specialist Sobi has enhanced its hematology portfolio with a $1.7 billion acquisition of Seattle-based CTI BioPharma and its myelofibrosis treatment Vonjo, a potential blockbuster that was approved last year. |
By James Waldron Bayer has taken its radiopharmaceutical pipeline up a gear, paying out $45 million upfront to Bicycle Therapeutics on a collaboration spanning multiple oncology targets. |
By Joseph Keenan The costs for Roche to decommission and demolish its former API manufacturing plant in County Clare, Ireland, continue to climb, with the bill now reaching €57.3 million ($62.7 million) over a three-year period. |
By Andrea Park With the sell-off of its applied science, food and enterprise services businesses now complete, PerkinElmer is charting a new path with its remaining diagnostics and life sciences divisions. |
By Nick Paul Taylor Boehringer Ingelheim has teased the obesity data that emboldened it to start gearing up for phase 3. Recipients of the Zealand Pharma-partnered prospect lost up to 14.9% of their weight after 46 weeks, but the data released so far make it hard to say how Boehringer compares to Eli Lilly and Novo Nordisk. |
By Helen Floersh Scientists have released the first draft of the human pangenome reference, a new blueprint of human DNA built on data from a much more diverse cohort than the original. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we discuss the rise of digital therapeutics and remaining barriers to implementation. We also talk about what it takes to fix the PBM industry. |
|
|---|
|
|
|
Thursday, May 25, 2023 | 10:00am ET / 7:00am PT Join the webinar and discover our MVA technology platform and explore the advantages for development and manufacturing of multiple vaccines and cell and gene therapeutics. Register now.
|
|
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperHow can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
